



**Centrexion Therapeutics Announces Oral Presentation of Six Month Efficacy Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Knee Osteoarthritis at the Annual European Congress of Rheumatology (EULAR 2017)**

**BOSTON, Mass.**, June 7, 2017 – Centrexion Therapeutics, a company focused on advancing the treatment of chronic pain with one of the largest exclusively pain-focused pipelines of non-opioid therapies in active development, today announced it will provide an oral presentation of 6-month data from a randomized, double-blind, placebo-controlled, dose-ranging study assessing the efficacy and safety of CNTX-4975 for the treatment of moderate to severe chronic knee pain associated with osteoarthritis at the European League Against Rheumatism’s Annual European Congress of Rheumatology (EULAR 2017) taking place June 14 – 17, 2017 in Madrid.

Details of the oral presentation are listed below.

**Title (OPO167): Efficacy And Safety Of CNTX-4975 in Subjects with Moderate To Severe Osteoarthritis Knee Pain: 24-Week, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study**

**Session:** Osteoarthritis: new horizons for treatment

**Presentation Time:** 10:50 a.m. CEST, June 15, 2017

**Location:** Room N117 / N118

***About CNTX-4975***

CNTX-4975 is based on Centrexion’s proprietary STRATI® technology (**S**ynthetic **T**Rans **c**Apsaicin **u**ltra-pure **I**njection), a highly potent, ultrapure, synthetic form of trans-capsaicin (a medicine traditionally derived from the chili plant). CNTX-4975 is designed to be injected directly into the site of pain to provide rapid onset, large reduction and long duration of relief from moderate to severe pain without affecting touch sensibility or position sense.

CNTX-4975 works by selectively targeting the capsaicin receptor (TRPV1) to rapidly inactivate only the local pain fibers transmitting signals to the brain. With a short half-life, STRATI® is cleared from the body within 24 hours. This approach provides pain relief that can last for months until the ends of the local pain fibers regenerate, while maintaining normal sensation, such as touch, pressure and position, and without the risks of toxicities of NSAIDs and injected corticosteroids or the side effects, including abuse and addiction, associated with opioid treatments.

***About Centrexion Therapeutics***

Centrexion Therapeutics, Corp. is focused on advancing the treatment of chronic moderate to severe pain with one of the largest exclusively pain-focused pipelines of non-opioid, non-addictive therapies in active development. Centrexion Therapeutics recognizes the needs of over a quarter of a billion people living with chronic pain worldwide, and aims to develop new, safer and more effective therapies that overcome the limitations and challenges associated with current pain treatments. Founded by world-renowned leaders in drug development and well-funded by key investors, Centrexion Therapeutics is building a pain treatment powerhouse to address the substantial and growing global chronic pain epidemic. Centrexion Therapeutics has recently relocated from Baltimore, Md. to Boston, Mass.



For more information about Centrexion, visit <http://www.centrexion.com>.

# # #

**Media Contact**

Julie Normart, Pure Communications, Inc.

+1 (415) 946-1087

[jnormart@purecommunications.com](mailto:jnormart@purecommunications.com)